Commentary | Published:

Stem cells—a hard sell to investors


A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading

Figure 1: Market performance of 5 'stem cell' companies illustrates the volatility of the group compared with the Nasdaq general biotech stock index.